Join
Live feed
·
PRReleasevia Quantisnow
Bicara Therapeutics Inc. logo

Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab in 1L HPV-negative R/M HNSCC at ESMO Asia 2025

ByQuantisnow·Wall Street's wire, on your screen.
BCAX· Bicara Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BCAX (Bicara Therapeutics Inc.) and more on Quantisnow.